# Jaguar Health Targets Mid-2027 MVID Filing

> Jaguar Health aims for mid-2027 drug submission after $10m debt cut.
- Title: Jaguar Health Targets Mid-2027 MVID Filing · TokenPost
- Summary: Jaguar Health aims for mid-2027 drug submission after $10m debt cut. Jaguar Health plans mid-2027 new drug application for pediatric MVID treatment after…
- Keywords: jaguar health, mvid, crofelemer, fda, breakthrough therapy, debt reduction, q3 2026, mytesi, canalevia-ca1, future pak, crypto, TokenPost
- URL: https://shortify.news/TokenPost/jaguar-health-targets-mid-2027-mvid-filing
- Source: TokenPost — https://tokenpost.com/news/business/59649
- Published: 2026-11-17T17:03:19+00:00
- Read time: 1 min
- Topics: jaguar health, mvid, crofelemer, fda, breakthrough therapy, debt reduction, q3 2026, mytesi, canalevia-ca1, future pak, crypto, finance
## Jaguar Health Targets MVID Filing
Jaguar Health plans mid-2027 new drug application for crofelemer to treat pediatric MVID after completing pivotal-trial enrollment.
## Debt Reduction Milestone
Jaguar reduced outstanding debt by more than $10 million in Q3 2026, with $2.343 million revenue and $9.23 net loss per share.
## Next Milestone
Jaguar targets mid-2027 NDA submission and seeks FDA breakthrough therapy designation for faster review.
## Key takeaway

Jaguar Health plans mid-2027 new drug application for pediatric MVID treatment after reducing debt by over $10 million.

---

Summary: Shortify — https://shortify.news/TokenPost/jaguar-health-targets-mid-2027-mvid-filing
Reporting: TokenPost — https://tokenpost.com/news/business/59649

When you use this summary, link the Shortify URL for the summary and credit the reporting to its newsroom.